Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020
Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy [...]
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML
Cullinan Oncology, German Cancer Research Center (DKFZ) and the [...]
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine [...]
Fueled with a fresh cash injection, Cullinan expands its pipeline with a bid to develop a new combination drug for the checkpoint class
Fueled with a fresh cash injection, Cullinan expands its pipeline [...]
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, [...]
Cullinan Oncology Completes $98.5 Million Series B Financing
Cullinan Oncology Completes $98.5 Million Series B Financing [...]
Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl
Cullinan Oncology Announces First Patients Dosed with Drug Candidates [...]
Cullinan Co-Founder Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy
Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy [...]
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop [...]
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The [...]
Cullinan Oncology Emerges with $150 Million and a Roster of All-Star Biotech Scientists
Cullinan Oncology, LLC emerged from stealth mode with $150 million in Series A financing as well as a new strategy for tackling oncological drug development - a financial strategy that seeks to mitigate developmental risk.
Cambridge biotech startup raises $150 million to develop cancer drugs
A pair of venture capital firms is investing $150 million in a Cambridge startup that hopes to develop cancer medicines using what it says is a new streamlined business model.